LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight [Yahoo! Finance]
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
Ocugen, Inc. (NASDAQ: OCGN) had its price target raised by analysts at Chardan Capital from $6.00 to $7.00. They now have a "buy" rating on the stock.
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs [Yahoo! Finance]